Form 4: Arcellx Director and 10% Owner Ali Behbahani Granted 9,174 Stock Options

Arcellx, Inc. Director and 10% Owner Ali Behbahani was granted 9,174 stock options with an exercise price of $63.68, vesting by May 29, 2026, or the next annual meeting.

Summary

• Ali Behbahani, a Director and 10% Owner of Arcellx, Inc. (ACLX), was granted 9,174 stock options on May 29, 2025.
• The stock options have an exercise price of $63.68 per share.
• One hundred percent (100%) of the shares subject to the award will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, contingent upon Mr. Behbahani's continued service as a Service Provider.
• The options have an expiration date of May 29, 2035.
• Following this transaction, Mr. Behbahani directly beneficially owns 9,174 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued alignment between management and shareholder interests, representing a standard and expected compensation practice.

Positives

• The grant of 9,174 stock options to a director and 10% owner aligns management incentives with long-term shareholder interests.
• The options have a 10-year expiration date (May 29, 2035), providing a substantial long-term incentive horizon for the director.

Risks

• The vesting of the stock options is contingent upon the reporting person's continued service as a Service Provider, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The grant of stock options to a director indicates a long-term incentive for the individual, aligning their future financial interests with the company's performance and potential stock price appreciation.

Industry Context

This filing reflects a standard equity incentive grant to a director, a common practice across industries, including biotechnology, to align leadership interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a common compensation practice across publicly traded companies, including those in the biotechnology sector, to incentivize long-term commitment and performance.
• The 10-year expiration period for the options is typical for such equity grants, providing a substantial window for value realization.
• The vesting schedule, tied to continued service and an annual meeting, is a standard mechanism to ensure retention and ongoing contribution from board members.

Related Party Transactions

• The grant of stock options to Ali Behbahani, a director and 10% owner, constitutes a related party transaction as part of his compensation package under the company's 2022 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with long-term shareholder value creation, potentially benefiting shareholders through improved company performance.
• Employees: While not directly impacting all employees, such grants are part of the company's overall equity incentive framework, which can influence employee morale and retention indirectly.

Next Steps

• The granted stock options will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, subject to the reporting person's continued service.

Key Dates

Recommendation

Keywords

Arcellx, ACLX, Stock Option, Insider Transaction, Form 4, Director, Beneficial Ownership, Equity Incentive Plan